Regeneron Pharmaceuticals (REGN) Short term Debt (2020)

Regeneron Pharmaceuticals (REGN) recorded quarterly Short term Debt of $1.5 billion in Q2 2020.

Regeneron Pharmaceuticals (REGN) Short term Debt (2020) Analysis & Trends

Regeneron Pharmaceuticals' Short term Debt history runs 1 years deep, the most recent figure standing at $1.5 billion for Q2 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	814,307.08 Bn	814,307.05 Bn	-
2	Belite Bio	55,320.00 Bn	55,320.00 Bn	-
3	Quantum Biopharma	17,149.72 Bn	17,149.72 Bn	-
4	Legend Biotech	3,590.00 Bn	3,589.71 Bn	242.10 Mn
5	Akari Therapeutics	1,650.72 Bn	1,650.72 Bn	-
6	Evaxion A	1,522.09 Bn	1,522.07 Bn	-
7	Psyence Biomedical	229.39 Bn	229.38 Bn	-
8	Vertex Pharmaceuticals	113.09 Bn	105.85 Bn	2.59 Bn
9	Abivax	90.15 Bn	90.15 Bn	-
10	Regeneron Pharmaceuticals	63.59 Bn	54.83 Bn	3.31 Bn

Download Data

Date	Value
Jun 30, 2020	1.50 Bn